Literature DB >> 21078056

Oxytocin to augment labour during home births: an exploratory study in the urban slums of Dhaka, Bangladesh.

A C Moran1, T Wahed, K Afsana.   

Abstract

OBJECTIVE: In Bangladesh, the majority of women give birth at home. There is anecdotal evidence that unqualified allopathic practitioners (UAPs) administer oxytocin at home births to augment labour pain. The objective is to explore the use of oxytocin to augment labour pain during home births in an urban slum in Dhaka, Bangladesh.
DESIGN: Cross-sectional survey.
SETTING: KamrangirChar slum, Dhaka, Bangladesh. POPULATION: Married women with a home birth or who experienced labour at home in the 6 months prior to the survey (n = 463) were interviewed. Twenty-seven UAPs were interviewed to validate women's responses.
METHODS: Bivariate and multivariate logistic regressions were used to identify significant predictors of oxytocin use. MAIN OUTCOME MEASURES: Reported use of oxytocin to augment labour pain.
RESULTS: Forty-six percent of women reported using medicine or other treatments to augment labour pain, 131 of whom reported using oxytocin (28% of total). Traditional birth attendants were the predominant decision-makers of when to use oxytocin. The medication was provided by a UAP who administered the drug via saline infusion or intramuscular injection. Higher education, lower parity, reported long labour (more than 12 hours), and knowledge of and positive attitudes towards oxytocin were significantly associated with oxytocin use after controlling for other factors. In the validation exercise, there was agreement about the use of oxytocin to augment labour in 22 of 27 cases (82%).
CONCLUSIONS: About one-third of women used oxytocin to augment labour pain. This practice has implications for health education as well as future research to assess the impact on adverse maternal and neonatal outcomes.
© 2010 The Authors Journal compilation © RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21078056     DOI: 10.1111/j.1471-0528.2010.02714.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

1.  Home deliveries and risk.

Authors:  Athol Kent
Journal:  Rev Obstet Gynecol       Date:  2011

2.  The perspectives of clients and unqualified allopathic practitioners on the management of delivery care in urban slums, Dhaka, Bangladesh - a mixed method study.

Authors:  Tasnuva Wahed; Allisyn C Moran; Mohammad Iqbal
Journal:  BMC Pregnancy Childbirth       Date:  2010-09-07       Impact factor: 3.007

3.  Reported Pain During Labour - A Qualitative Study of Influencing Factors among Parturient During Confinement in Private or Government Hospital.

Authors:  S Parthasarathy; M Ravishankar; V R Hemanthkumar
Journal:  J Clin Diagn Res       Date:  2016-03-01

4.  Management of uterine rupture: a case report and review of the literature.

Authors:  Thomas Obinchemti Egbe; Gregory Edie Halle-Ekane; Charlotte Nguefack Tchente; Jacques Ernest Nyemb; Eugene Belley-Priso
Journal:  BMC Res Notes       Date:  2016-11-21

5.  Perinatal mortality associated with use of uterotonics outside of Comprehensive Emergency Obstetric and Neonatal Care: a cross-sectional study.

Authors:  Louise T Day; Daniel Hruschka; Felicity Mussell; Eva Jeffers; Stacy L Saha; Shafiul Alam
Journal:  Reprod Health       Date:  2016-10-06       Impact factor: 3.223

6.  Improving quality of care for maternal and newborn health: a pre-post evaluation of the Safe Childbirth Checklist at a hospital in Bangladesh.

Authors:  Herfina Y Nababan; Rubana Islam; Shabnam Mostari; Md Tariqujjaman; Malabika Sarker; Mohammad Tajul Islam; Corrina Moucheraud
Journal:  BMC Pregnancy Childbirth       Date:  2017-12-04       Impact factor: 3.007

7.  Knowledge, attitudes, and practices related to uterotonic drugs during childbirth in Karnataka, India: a qualitative research study.

Authors:  Nitya Nand Deepak; Ellie Mirzabagi; Alissa Koski; Vandana Tripathi
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.